PHP
NEO icon

Parkman Healthcare Partners’s NeoGenomics NEO Stock Holding History

Parkman Healthcare Partners’s Portfolio NEO Stock Details NEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-237,762
Closed -$3.85M – 112
2023
Q4 		$3.85M Sell
237,762
-8,050
-3% -$132K 0.54% 59
2023
Q3 		$3.02M Buy
245,812
+9,965
+4% +$148K 0.55% 53
2023
Q2 		$3.79M Buy
+235,847
New +$3.89M 0.66% 48

Other funds holding NEO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $2.23B AUM 12.38% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Parkman Healthcare Partners's NEO Position: Q1 2024 in Review

Parkman Healthcare Partners sold out of NeoGenomics (NEO) in Q1 2024, closing a stake of 237,762 shares — an estimated $3.85M sold.

Parkman Healthcare Partners first reported a position in NEO in Q2 2023 and held it in 3 quarters. The position peaked at $3.85M in Q4 2023. 263 funds tracked by Wall St. Rank hold NEO as of Q1 2024.

  • Parkman Healthcare Partners reported no remaining NeoGenomics position as of Q1 2024 after selling out during the quarter.
  • Parkman Healthcare Partners sold 237,762 NeoGenomics shares in Q1 2024, an estimated $3.85M.
  • Parkman Healthcare Partners first reported a position in NeoGenomics in Q2 2023 and held it in 3 quarters.
  • Parkman Healthcare Partners's NeoGenomics position peaked at $3.85M in Q4 2023.
  • 263 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2024.

Based on Parkman Healthcare Partners's 13F filing for Q1 2024, filed 15 May 2024.